Condition: Dengue Fever · Sponsor: George Washington University
ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.
This description comes directly from the study's public registry record.
Aileen Y Chang, MD · 202-741-6562 · chang@email.gwu.edu
Alfonso Sucerquia, MD · 202-741-6562 · alfonso.sucerquiahernandez@email.gwu.edu
Always discuss trial participation with your own doctor first.
| Cien Salud IPS SAS | Barranquilla, Atlántico, Colombia | Active Not Recruiting |
| Clinica de la Costa SAS | Barranquilla, Colombia, Colombia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04597437